TABLE 4.
Pharmacokinetic parameter estimates for the final models and Bootstrap results.
| Parameters | Final model | Bootstrap | Bias (%) | |||
|---|---|---|---|---|---|---|
| Estimate | RSE (%) | 95%CI | Median | 95%CI | ||
| Theory-based compartmental model | ||||||
| Ka (h−1) | 4.48 fixed | — | — | 4.48 fixed | — | — |
| CLPl/F (L h−1) | 234 | 45.7 | 24.28–443.72 | 231.12 | 203.96–283.56 | −0.23 |
| θDDmax | 3.51 | 55.8 | 0.332–7.352 | 3.51 | 3.09–4.39 | 0 |
| θDD50 | 2.44 | 25 | 1.244–3.636 | 2.45 | 1.43–3.95 | 1.14 |
| θAST | (−0.216) | 19.8 | (−0.3)-(-0.312) | (-0.211) | (−0.299)-(−0.139) | −2.31 |
| θVRCZ | (−0.575) | 17 | (−0.766)-(−0.384) | (−0.571) | (−0.871)-(−0.312) | −0.69 |
| θCYP3A5*1 | 0.168 | 37.1 | 0.046–0.29 | 0.167 | 0.056–0.299 | −0.59 |
| VPl/F (L) | 11000 | 10.8 | 8,667.6–13332.4 | 10822.2 | 8,696.0–13072.5 | −1.62 |
| θPOD | 0.887 | 12.3 | 0.673–1.101 | 0.886 | 0.727–1.159 | −0.11 |
| Between subject variability | ||||||
| ωCLpl/F (%) | 29.7 | 8.2 | — | 29.2 | 24.5–34.4 | −1.68 |
| ωVpl/F (%) | 59.2 | 11.5 | — | 59.1 | 39.3–71.3 | −0.17 |
| Residual unexplained error | ||||||
| δ1 (%) | 30.8 | 7.7 | — | 30.7 | 28.2–32.9 | −0.32 |
| MM model | ||||||
| Vm (mg day−1) | 6.62 | 5.2 | 5.952–7.288 | 6.63 | 6.03–7.50 | 0.15 |
| Km (ng ml−1) | 6.46 | 14 | 4.686–8.234 | 6.45 | 4.90–8.73 | −0.15 |
| θPOD | 0.277 | 22.6 | 0.154–0.4 | 0.272 | 0.152–0.404 | −1.80 |
| θHCT | 1.16 | 22.8 | 0.641–1.679 | 1.14 | 0.598–1.685 | −1.72 |
| θTBIL | 0.286 | 23 | 0.157–0.415 | 0.281 | 0.156–0.429 | −1.75 |
| θCYP3A5*1 | (-0.365) | 19.4 | (−0.504)–(−0.226) | (−0.362) | (−0.500)–(−0.210) | −0.82 |
| θVRCZ | 2.15 | 42.3 | 0.368–3.932 | 2.13 | 0.554–4.417 | −0.93 |
| Between subject variability | ||||||
| ωKm | 65.3% | 7.8 | — | 64.7% | 55.3%–74.1% | −0.92 |
| Residual unexplained error | ||||||
| δ1 (%) | 20.4 | 10.5 | — | 20.2 | 14.4–24.4 | −0.098 |
| δ2 (mg day−1) | 0.568 | 10.2 | — | 0.559 | 0.436–0.699 | −1.58 |
CLPl/F, the apparent plasma clearance; VPl/F, the apparent plasma volume of distribution; Ka, absorption rate constant; Vm, the maximum dose rate (daily dose) at the steady state; Km, the Michaelis constant which denotes the steady-state trough concentration at half-maximal dose rate; ω, between subject variability; δ1, proportional residual error; δ2, additive residual error; θ, the coefficient of the included covariates on the parameters; CI, confidence interval; RSE, relative standard error; CYP3A5*1, CYP3A5*1*3 and CYP3A5*1*1 expresser; MM, Michaelis-Menten; Bias, prediction error.
Where NONMEM, represents the PK, parameters estimates of the final model and Bootstrap represents the PK, parameters median values obtained from the nonparametric bootstrap procedure.